2020 has been a challenging year for all industries. For pharma and its HCP customers even more so. All eyes are on the companies developing vaccines and drugs for treatment of COVID-19, while doctors have closed their doors for pharma reps. Long established processes have been disrupted and complex market strategies have been rendered useless. Each pharma no matter big or small, innovative, or generic, had to improvise and come up with contingency plans to save the year. Some have been slower waiting for the old ways to come back, others have been more agile experimenting with digital and expanding boundaries, most are in the middle digitally curious but not risking too much.

“Sales at Any Cost” is Not Sustainable in the Long Run

For commercial organisations, profits are important. But it cannot be 'at any cost' and certainly not at the cost of human life. As healthcare providers helping to mitigate the pain and misery of millions of human beings, we need to remember that charity begins at home.

Customer Acquisition Cost (CAC) & Indian Pharma

Introduction Customer Acquisition Cost (CAC) is a key metric representing...

How Smart Medical Reps Can Beat Bots

Today's Brand Equity cover — a woman lost in...

Contact Us
Terms of Service
Privacy Statement

Facebook

Twitter

Youtube

Healthcare Trends

Subhendu K Datta has taken on a new role as Senior Vice President (Sales & Marketing) – India & Nepal SBU Head at Micro...

In his new position, he will lead teams across...

Why Private Equity is the New Kingmaker in Pharma & MedTech

The PE Playbook: Why Private Equity is the New...

Tez Health and the New Race to Bring Healthcare Home

Tez Health and the New Race to Bring Healthcare...

Is Pharma M&A Slowing Down Amidst Geopolitical Friction?

The pharmaceutical industry stands at a critical juncture in...

Will the GLP Battle Now Shift from Injectable to Oral?

In India’s million-strong retail pharmacy universe, oral weight-loss pills...

Marketing

Subhendu K Datta has taken on a new role as Senior Vice President (Sales & Marketing) – India & Nepal SBU Head at Micro...

In his new position, he will lead teams across...

Why Private Equity is the New Kingmaker in Pharma & MedTech

The PE Playbook: Why Private Equity is the New...

Tez Health and the New Race to Bring Healthcare Home

Tez Health and the New Race to Bring Healthcare...

Is Pharma M&A Slowing Down Amidst Geopolitical Friction?

The pharmaceutical industry stands at a critical juncture in...

Will the GLP Battle Now Shift from Injectable to Oral?

In India’s million-strong retail pharmacy universe, oral weight-loss pills...

Policies/Sales

Subhendu K Datta has taken on a new role as Senior Vice President (Sales & Marketing) – India & Nepal SBU Head at Micro...

In his new position, he will lead teams across...

Why Private Equity is the New Kingmaker in Pharma & MedTech

The PE Playbook: Why Private Equity is the New...

Tez Health and the New Race to Bring Healthcare Home

Tez Health and the New Race to Bring Healthcare...

Is Pharma M&A Slowing Down Amidst Geopolitical Friction?

The pharmaceutical industry stands at a critical juncture in...

Will the GLP Battle Now Shift from Injectable to Oral?

In India’s million-strong retail pharmacy universe, oral weight-loss pills...

Strategy

Subhendu K Datta has taken on a new role as Senior Vice President (Sales & Marketing) – India & Nepal SBU Head at Micro...

In his new position, he will lead teams across...

Why Private Equity is the New Kingmaker in Pharma & MedTech

The PE Playbook: Why Private Equity is the New...

Tez Health and the New Race to Bring Healthcare Home

Tez Health and the New Race to Bring Healthcare...

Is Pharma M&A Slowing Down Amidst Geopolitical Friction?

The pharmaceutical industry stands at a critical juncture in...

Will the GLP Battle Now Shift from Injectable to Oral?

In India’s million-strong retail pharmacy universe, oral weight-loss pills...

Thought Leadership
Healthcare C-Suite Movements
Digital in Pharma
Events
- FFE+CEO RT
- BrandStorm
Solutions & Pricing
Partner

Hot topics

The ₹5 Snack SKU: A Silent Indian Metabolic Crisis

Executive Summary — The Paradox of Scale In the annals...

Trump Tariff and the Trade Turbulence – A Salil Kallianpur Blog

Impact of Trump’s 100% tariff on imported patented/innovative drugs...

How to Harness the Power of Omnichannel Marketing in the Pharma Industry

Pharmaceutical & medical devices Industry is fast adapting to these changes at various levels of the value chain. Billions of dollars are being spent on digital transformation projects ranging from usage of AI & ML in product development, production and predictive maintenance, Blockchain in supply chain and data management & analytics in strategic decision making. This article focuses on Omnichannel marketing, one of the key digital transformations that the industry is learning and implementing at a rapid pace. Omnichannel Marketing: Promise and Possibilities An industry that historically focused all their brand building and market shaping efforts through F2F meetings & medical education programs has started making giant strides in multi-channel strategy now. A digital journey that started with an e-detailing platform has progressed fast by adding brand websites, Approved E-Mails, social media, webinars and other media effectively creating a multi-channel strategy. The only hindside to this is, all these channels work independently, expecting HCPs to find and sort out information themselves.